⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADXN News
Addex Therapeutics Ltd American Depositary Shares
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
globenewswire.com
ADXN
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
globenewswire.com
ADXN
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
globenewswire.com
ADXN
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
globenewswire.com
ADXN
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
globenewswire.com
ADXN
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
globenewswire.com
ADXN
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
globenewswire.com
ADXN
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
globenewswire.com
ADXN
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
globenewswire.com
ADXN
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
globenewswire.com
ADXN